Advertisement

Search Results

Advertisement



Your search for ,dUe matches 5447 pages

Showing 5201 - 5250


gynecologic cancers
issues in oncology

American College of Physicians Issues Guideline Recommending Against Routine Pelvic Exams for Asymptomatic Women

A new evidence-based clinical practice guideline from the American College of Physicians (ACP) is recommending that physicians should not offer routine pelvic examinations to asymptomatic, average-risk, nonpregnant women. The recommendation stems from a review of 52 published articles from 1946...

pancreatic cancer

No Benefit of Adding Telomerase Peptide Vaccine to Chemotherapy in Patients With Advanced Pancreatic Cancer

In a UK phase III TeloVac trial reported in The Lancet Oncology, Middleton et al found that the sequential or concurrent addition of the telomerase peptide vaccine GV1001 to gemcitabine/capecitabine did not improve survival in patients with locally advanced or metastatic pancreatic cancer. GV1001...

colorectal cancer

Synthetic Triterpenoids Show Promise in Preventing Colitis-Associated Colon Cancer in Preclinical Study

Researchers from Case Western Reserve and Dartmouth have shown that a class of small antioxidant molecules carries promise for suppressing colon cancer associated with colitis. These preclinical findings, published in the Journal of Clinical Investigation, offer hope that physicians ultimately will ...

colorectal cancer

Surgical Treatment Delay May Not Result in Worse Outcomes in Patients With Colon Cancer

A “reasonable” delay prior to surgery for colon cancer may not result in worse outcomes, according to the results of a retrospective study presented by Amri et al in the Annals of Surgical Oncology. Flexibility in scheduling surgery may lead to an improvement in the quality and safety...

pancreatic cancer

Priming Pancreatic Cancer Cells With a Vaccine May Allow Them to Respond to Immunotherapy

Pancreatic ductal adenocarcinoma is considered a “nonimmunogenic” neoplasm and does not typically respond to immunotherapy, in part due to a complex tumor microenvironment that provides a formidable barrier to immune infiltration and function. A new study by Lutz et al has found that by ...

lung cancer

Phase III Trial of Adding Figitumumab to Chemotherapy in Advanced Nonadenocarcinoma NSCLC Stopped Early for Futility and Increased Harm

In the first phase III trial assessing the combination of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor with chemotherapy as first-line treatment for advanced nonadenocarcinoma non–small cell lung cancer (NSCLC), the addition of the fully human immunoglobulin G2 monoclonal...

colorectal cancer

Palliative Resection of Primary Tumor May Improve Survival in Patients With Metastatic Colorectal Cancer

Palliative resection of the primary tumor was associated with a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic colorectal cancer, according to the results of a study reported in the Annals of Surgical Oncology. Gresham et al noted...

breast cancer
issues in oncology

ASCO 2014: Women With Breast Cancer and Bone Metastasis Can Safely Scale Back Frequency of Zoledronic Acid Dosing

Findings from a phase III randomized study suggest that women with breast cancer and bone metastasis who have received at least nine doses of zoledronic acid over the previous year can safely scale back dosing from every 4 weeks to every 12 weeks without compromising the effectiveness of the...

head and neck cancer

ASCO 2014: Lower-Dose Radiation May Reduce Long-Term Side Effects Without Compromising Survival in Certain HPV-Positive Head and Neck Cancers

According to a phase II study, customizing radiation doses based on response to induction chemotherapy and other prognostic factors may allow lower doses of radiation therapy to be administered to some patients with human papillomavirus (HPV)-positive oropharyngeal cancer without compromising...

breast cancer

Early Change in Chemotherapy Based on Elevated Circulating Tumor Cells Does Not Improve Outcome in Metastatic Breast Cancer

Elevated circulating tumor cells are associated with poor prognosis in metastatic breast cancer. In the phase III Southwest Oncology Group (SWOG) S0500 trial reported in the Journal of Clinical Oncology, Smerage et al assessed whether changing chemotherapy after one cycle of first-line treatment in ...

skin cancer

ASCO 2014: PD-1–Targeting Antibody Pembrolizumab Produces Long-Term Responses in Patients With Metastatic Melanoma

Findings from a large phase I study of 411 patients with advanced melanoma show that the PD-1–targeting antibody pembrolizumab (MK-3475) produced responses in 34% of patients, including 28% of patients whose disease progressed on prior treatment with ipilimumab (Yervoy). Among those who...

skin cancer

ASCO 2014: Adjuvant Ipilimumab Significantly Improves Recurrence-Free Survival in Patients With High-Risk Stage III Melanoma

Adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival, the primary endpoint of the phase III EORTC 18071/CA 184-029 study. Patients randomly assigned to receive ipilimumab had a 9-month absolute improvement in...

breast cancer

Adjuvant! Online Performs Poorly in Older Patients With Breast Cancer in Dutch Study

In a Dutch population-based study reported in The Lancet Oncology, de Glas et al found that the Adjuvant! Online prediction tool performed poorly in older patients with early-stage breast cancer, significantly overestimating or underestimating overall survival depending on comorbidity...

lung cancer

ASCO 2014: Ceritinib Shows Rapid, Durable Response in ALK-Positive NSCLC

In a phase I study, ceritinib (Zykadia) was found to shrink tumors in patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC), regardless of whether patients had received previous treatment with an ALK inhibitor. The study was presented at the 2014 ASCO...

prostate cancer

ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer

The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...

pancreatic cancer

Central Pancreatectomy for Low-Grade Neoplasms Results in 'Excellent' Pancreatic Function but Substantial Morbidity

The availability of cross-sectional imaging has resulted in increased diagnosis of low-grade pancreatic neoplasms and use of central pancreatectomy as an alternative to standard resection for such lesions. In a French single-center experience reported in JAMA Surgery, Goudard et al found that...

colorectal cancer

No Differences in Surgical Outcomes With Four Different Chemotherapy Regimens Plus Preoperative Radiotherapy in Rectal Cancer

As reported in the Journal of Clinical Oncology by O’Connell et al, the National Surgical Adjuvant Breast and Bowel Project (NSABP) Trial R-04 is assessing four chemotherapy regimens given concurrently with preoperative radiotherapy in order to help identify optimal treatment in patients with ...

hepatobiliary cancer

More Toxicity Associated With Addition of Sorafenib to Yttrium-90 Radioembolization Prior to Liver Transplantation

The addition of sorafenib (Nexavar) to yttrium-90 radioembolization was associated with higher rates of biliary complications and potentially more acute rejections prior to transplantation in patients with hepatocellular carcinoma, according to the results of a prospective randomized pilot study....

pancreatic cancer

Early Study Shows Improved Survival With Radioimmunotherapy/Gemcitabine Combination in Patients With Advanced Pancreatic Ductal Cancer

A randomized phase Ib study of a combination of low radiosensitizing doses of gemcitabine and fractionated doses of 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic ductal cancer who had received at least two prior systemic therapies, has found a significant survival advantage in...

solid tumors
bladder cancer

Accelerated Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim Is Effective, Well-Tolerated Neoadjuvant Therapy for Bladder Cancer

Although neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer, it is not widely used due to concerns over toxicity and delayed cystectomy. In a phase II trial reported in the Journal of Clinical Oncology, Plimack et al evaluated whether a neoadjuvant...

solid tumors
bladder cancer

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim: Safe and Effective in Muscle-Invasive Urothelial Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that a neoadjuvant four-cycle/8-week regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and effective in patients with muscle-invasive urothelial cancer. Study Details ...

hematologic malignancies

Epigenetically Reprogrammed Cells Generate Functional Cord Blood Stem Cells for Transplantation

The use of cord blood cells as hematopoietic stem cell grafts for patients with hematologic malignancies receiving an allogeneic stem cell transplant has been limited to children due to the small number of stem cells present in a single cord blood collection. The result of these limitations has...

gynecologic cancers

Researchers Identify Enzymes Associated With Chemoresistance in Ovarian Cancer

Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in patients with ovarian cancer, according to research by Cacan et al. The study investigated the silencing of RGS10 expression in ovarian cells by epigenetics and identified two epigenetic regulators,...

breast cancer

Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Previously Treated Advanced HER2-Positive Breast Cancer

There are few treatment options for breast cancer patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic disease. In the open-label phase III TH3RESA trial reported in The Lancet Oncology by Krop and et al, ado-trastuzumab emtansine (Kadcyla)...

head and neck cancer

Increased Incidence of Thyroid Cancer: An Epidemic of Diagnosis?

In a study reported in JAMA Otolaryngology Head & Neck Surgery, Davies and Gilbert found that the incidence of thyroid cancer has nearly tripled since 1975. However, the increase appears to represent an “epidemic of diagnosis” and to almost exclusively represent increased diagnosis...

breast cancer

Surgery for Metastatic Breast Cancer Associated With High Complication Rate

Surgery for metastatic breast cancer conveys a significantly increased risk for morbidity and mortality at 30 days vs surgery for earlier-stage disease, according to researchers from the University of Toronto who presented their findings at the American Society of Breast Surgeons Annual Meeting in...

head and neck cancer

Black Patients With Salivary Gland Mucoepidermoid or Squamous Cell Carcinoma Have Poorer Disease-Specific Survival Than White Patients

In a retrospective study of salivary gland cancer survival reported in JAMA Otolaryngology Head & Neck Surgery, Russell et al found black patients with mucoepidermoid or squamous cell carcinoma have poorer disease-specific survival than white patients, with no difference being observed between...

Anti–Interleukin-1 Alpha Antibody MABp1 Is Well Tolerated, Safe, and Active in Phase I Trial in Refractory Cancers

Expression of the inflammatory cytokine interleukin (IL)-1 alpha is a very early step in the inflammatory response that characterizes the malignant phenotype and that is associated with angiogenesis, tumor invasiveness, metastasis, and cachexia. In a phase I dose-escalation study reported in The...

gastroesophageal cancer

Irradiated Stents Prolong Survival and Reduce Dysphagia Compared With Conventional Stents as Palliative Treatment in Unresectable Esophageal Cancer

In a single-blind phase III trial reported in The Lancet Oncology, Zhu et al compared the use of 125iodine seed–loaded vs conventional covered stents along with single high-dose brachytherapy as palliative treatment in patients with unresectable esophageal cancer. Use of the irradiated stents ...

issues in oncology

Novel DNA Vaccine Generates Immunity Against Tumor Vasculature Protein in Preclinical Study

Researchers from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania have employed a novel DNA vaccine that indirectly kills cancer cells by targeting a protein found in the tumor vasculature. The vaccine also indirectly creates an immune response to the ...

head and neck cancer

Sorafenib Improves Progression-Free Survival in Progressive Radioactive Iodine–Refractory Differentiated Thyroid Cancer

Patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer have a poor prognosis. In the double-blind phase III DECISION trial reported in The Lancet, Brose et al found that sorafenib (Nexavar) increased progression-free survival in this setting. The...

leukemia

FDA Grants Orphan Drug Designation to Alvocidib for the Treatment of Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to alvocidib, a potent cyclin-dependent kinase small-molecule inhibitor, for the treatment of patients with acute myeloid leukemia (AML). The agent is being tested in patients with intermediate- or high-risk AML, who...

breast cancer

Adding Everolimus to Trastuzumab/Vinorelbine Prolongs Progression-Free Survival but Increases Toxicity in Trastuzumab-Resistant Advanced Breast Cancer

Disease progression in HER2-positive breast cancer treated with trastuzumab (Herceptin) may be associated with PI3K/Akt/mTOR pathway activation, and use of an mTOR inhibitor might restore trastuzumab sensitivity. In the double-blind phase III BOLERO-3 trial reported in The Lancet Oncology,...

breast cancer

Use of Intraoperative Frozen Section Margin Assessment May Decrease Reoperations in Breast Cancer Patients Undergoing Lumpectomy

In female patients undergoing breast cancer lumpectomies, intraoperative frozen section margin assessment has been shown to decrease overall reoperation rates, according to the results of a study reported by Boughey et al in the journal Surgery. This finding may lead to lower health-care costs, a...

hematologic malignancies
supportive care

Addition of Tigecycline to Empiric Therapy Improves Success Rate in Febrile Neutropenic Patients With Hematologic Malignancy

Antibiotic monotherapy is considered standard in empiric therapy in febrile neutropenic cancer patients, but the approach may be insufficient given the increase in infections due to multidrug-resistant microorganisms. Tigecycline (Tygacil), the first in a new class of glycylcycline antibiotics, has ...

lung cancer
issues in oncology

‘Too Much and Too Little Care’ in Pulmonary Nodule Evaluation

Pulmonary nodules are common and many more will be found with implementation of lung cancer screening. In a retrospective cohort study reported in JAMA Internal Medicine, Wiener et al found that patients with pulmonary nodules were at high risk of both underevaluation and overevaluation for cancer, ...

leukemia

Volasertib Granted Orphan Drug Designation for Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Volasertib is currently being evaluated in a phase III clinical trial for the treatment of patients aged 65 or older, with previously untreated AML, who are ineligible for ...

breast cancer
lung cancer
issues in oncology

Breast Cancer Risk Variant Associated With Increased Lung Cancer Risk in Women

In a study reported in the Journal of the National Cancer Institute, Park et al examined single nucleotide polymorphisms (SNPs) associated with other cancers for potential associations with lung cancer. They found that the breast cancer SNP LSP1 rs3817198 was associated with significant risk of...

prostate cancer

Study Finds a Quarter of Men Drop Out of Prostate Cancer Monitoring, Casting Doubt on Safety of Active Surveillance

Noncompliance appears to be a major challenge for active surveillance, according to the results of long-term follow-up of patients with prostate cancer presented at the European Association of Urology 29th Annual Congress in Stockholm. Over a quarter of men dropped out of the active surveillance...

supportive care

ASCO Releases Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers

The American Society of Clinical Oncology has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology. The overall incidence of chemotherapy-induced peripheral neuropathy ...

colorectal cancer

Worse Progression-Free Survival With Addition of Cetuximab to Chemotherapy in Patients With Resectable Colorectal Liver Metastasis

Surgery for liver metastasis from colorectal cancer is associated with overall survival of approximately 40% at 5 years, and progression-free survival is increased with the addition of oxaliplatin and fluorouracil (5-FU). The addition of cetuximab (Erbitux) to chemotherapy has produced a survival...

lung cancer

Long-Term Hormone Therapy Is Associated With Improved Survival in Women With Non‒Small Cell Lung Cancer

In women with non–small cell lung cancer, long-term hormone therapy, particularly estrogen plus progesterone, is associated with improved survival, according to the results of a retrospective study presented by Katcoff et al in the Journal of Thoracic Oncology. This finding may lead to...

solid tumors
supportive care

Consumptive Hypothyroidism in GIST Associated With Increased D3 Expression

In a report in The New England Journal of Medicine, Maynard et al discuss identification of consumptive hypothyroidism due to overexpression of thyroid hormone–inactivating enzyme type 3 iodothyronine deiodinase (D3) in a patient with gastrointestinal stromal tumor (GIST) and subsequent...

head and neck cancer

Prognosis of HPV-Positive Head and Neck Cancer Varies According to Tumor Site

Patients with cancer of the throat and who are positive for the human papillomavirus (HPV) have a good prognosis, but until now the effect of being HPV-positive on the prognosis of tumors located elsewhere in the head and neck was unknown. A new study presented at the 33rd Conference of the...

prostate cancer
issues in oncology

New Test Developed to Detect Men at High Risk of Prostate Cancer Recurrence

A new genetic signature to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, according to a study presented at the 33rd Conference of the European Society for Radiotherapy and Oncology in...

issues in oncology
colorectal cancer

HLA Class I Antigen Expression Predicts Overall Survival Benefit With Aspirin Use in Colon Cancer

In a cohort study reported in JAMA Internal Medicine, Reimers et al found that aspirin use was associated with a significant 47% reduction in mortality risk after diagnosis of colon cancer expressing HLA class I antigen. There was no difference in aspirin benefit according to strong or weak...

gynecologic cancers

Findings of AURELIA Trial Support Consideration of Bevacizumab/Chemotherapy in Carefully Selected Patients With Platinum-Resistant Ovarian Cancer

The recently reported open-label phase III AURELIA trial showed that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvements in progression-free survival, the primary study endpoint, and objective response rate in women with recurrent platinum-resistant ovarian...

gynecologic cancers

Adding Bevacizumab to Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer

Single-agent chemotherapy is standard in platinum-resistant ovarian cancer. In the open-label phase III AURELIA trial reported in the Journal of Clinical Oncology, Pujade-Lauraine et al found that the addition of bevacizumab (Avastin) to chemotherapy resulted in significant improvement in...

gastroesophageal cancer

Radiofrequency Ablation Reduces Risk of High-Grade Dysplasia and Adenocarcinoma vs Endoscopic Surveillance in Patients With Barrett’s Esophagus

Barrett’s esophagus with low-grade dysplasia increases risk of esophageal adenocarcinoma. In a European study reported in JAMA, Phoa et al assessed whether endoscopic radiofrequency ablation reduced the rate of neoplastic progression compared with endoscopic surveillance in patients with...

issues in oncology
lung cancer

Phase II Trial Shows Feasibility of Customized Adjuvant Treatment in NSCLC, but Phase III Trial Canceled Due to Unreliability of ERCC1 Readouts

In the phase II Tailored Postsurgical Therapy in Early-Stage NSCLC (TASTE) trial (IFCT-0801), reported in the Journal of Clinical Oncology, Wislez et al examined the feasibility of customized adjuvant treatment based on EGFR mutation status and expression of ERCC1 (excision repair...

Advertisement

Advertisement




Advertisement